Trial Profile

Phase 1/2 clinical trial of CMP-SYNGAP-01 in SYNGAP patients.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CMP SYNGAP 01 (Primary)
Indications CNS disorders
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors CAMP4 Therapeutics

Most Recent Events

27 Jul 2026 According to the CAMP4 Therapeutics Media Release, the company has received clearance from Australia's therapeutic goods administration (TGA) and local HREC to initiate the study
08 May 2026 According to a CAMP4 Therapeutics Corp. media release, Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026.
31 Oct 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com